Literature DB >> 12548530

Early prednisone treatment in Duchenne muscular dystrophy.

Luciano Merlini1, Alessandro Cicognani, Elisabetta Malaspina, Monia Gennari, Saverio Gnudi, Beril Talim, Emilio Franzoni.   

Abstract

The purpose of this long-term, open parallel-group, double-consent study of alternate-day, low-dose prednisone in 2-4-year-old patients with Duchenne muscular dystrophy (DMD) was to determine whether prednisone produces a beneficial effect when given earlier than usual. Muscle function was evaluated by timed tests, and muscle strength with a hand-held myometer. After 55 months of treatment, the five patients (mean age 8.3 years) in the prednisone group were still able to get up from the floor, whereas two of the three in the control group had lost this ability. Side effects included a decline in growth rate in the prednisone-treated patients and excessive weight gain in one control and three treated patients. Because steroids are effective in prolonging function, but not in recovering lost function, we propose that treatment be started with low-dose prednisone in DMD patients as soon as the diagnosis is definite.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548530     DOI: 10.1002/mus.10319

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  26 in total

1.  Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice.

Authors:  Alison R Amenta; Atilgan Yilmaz; Sasha Bogdanovich; Beth A McKechnie; Mehrdad Abedi; Tejvir S Khurana; Justin R Fallon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

4.  Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.

Authors:  Kenji Rowel Q Lim; Yusuke Echigoya; Tetsuya Nagata; Mutsuki Kuraoka; Masanori Kobayashi; Yoshitsugu Aoki; Terence Partridge; Rika Maruyama; Shin'ichi Takeda; Toshifumi Yokota
Journal:  Mol Ther       Date:  2018-10-19       Impact factor: 11.454

5.  Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies.

Authors:  Nigel G Laing; Mark R Davis; Klair Bayley; Sue Fletcher; Steve D Wilton
Journal:  Clin Biochem Rev       Date:  2011-08

6.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

Review 7.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

8.  Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry.

Authors:  Jenna M Kastenschmidt; Ileen Avetyan; S A Villalta
Journal:  Methods Mol Biol       Date:  2018

9.  Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.

Authors:  Molly M Lamb; Nancy A West; Lijing Ouyang; Michele Yang; David Weitzenkamp; Katherine James; Emma Ciafaloni; Shree Pandya; Carolyn DiGuiseppi
Journal:  J Pediatr       Date:  2016-03-30       Impact factor: 4.406

Review 10.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.